Drug Information Association Logo

DIA Names Quintiles’ J. Rick Turner New Editor-In-Chief of the Drug Information Journal

Horsham, PA, USA — Feb 2, 2011

DIA today announced the appointment of J. Rick Turner, PhD, Senior Scientific Director, Cardiac Safety Services, Quintiles, as new editor-in-chief of the Drug Information Journal, the official peer-reviewed journal of DIA.

Since its inception, the Drug Information Journal has been largely focused on drugs. Dr. Turner intends to broaden its scope by publishing articles related to some new and hot topics including medical devices and medical device/drug combination products, companion diagnostics, and integrated pharmaceutical medicine, all with a focus on regulatory science.

“Our ultimate goal is to take care of patients, and while pharmaceutical medicine remains extremely important, the convergence of several lines of medical products plays a very large and potentially increasing role in improving human health in general,” says Dr. Turner. “I want to get much more input from all stakeholders so that the Drug Information Journal sits at the top of everyone’s must-read list.”

Dr. Turner is an experimental research scientist, clinical trialist, and author. Prior to joining Quintiles, He was a clinical submissions scientist at GlaxoSmithKline and president and chief scientific officer at Turner Medical Communications LLC.

Dr. Turner has been published in numerous pharmaceutical professional journals and peer-reviewed publications, including the American Heart Journal and Journal for Clinical Studies, and recently authored the second edition of New Drug Development: An Introduction to Clinical Trials (Springer Science, 2010). In 2003, he was a joint recipient of the American Journal of Nursing’s “Book of the Year” Award for Health & Behavior in Childhood & Adolescence (Springer, 2002).

Among other honors, Dr. Turner was awarded the Distinguished Scientific Award for Early Career Contributions to Psychophysiology from The Society for Psychophysiological Research and the Distinguished Scientific Award for Early Career Contributions to Psychosomatic Medicine from The American Psychosomatic Society. He currently holds appointments as Senior Fellow, Center for Medicine in the Public Interest and Affiliate Clinical Associate Professor, University of Florida College of Pharmacy.






ABOUT DIA: DIA is the global connector in the life sciences product development process. Our association of more than 18,000 members builds productive relationships by bringing together regulators, innovators and influencers to exchange knowledge and collaborate in an impartial setting. DIA’s network creates unparalleled opportunities for the exchange of knowledge and has the interdisciplinary experience to prepare for future developments. The dedicated efforts of DIA staff, members and speakers enable DIA to provide a comprehensive catalogue of conferences, workshops, training courses, scientific publications and educational materials. DIA is a global community representing thousands of stakeholders working together to bring safe and effective products to patients. DIA is an independent, nonprofit organization with its global center in Washington, D.C., USA; regional offices covering North and South America (Horsham, Penn., USA); Europe, North Africa and the Middle East (Basel, Switzerland); and Japan (Tokyo), India (Mumbai) and China (Beijing). For more information, visit www.diahome.org.